By Joel Hesch, Liberty University
The government has honed in on three primary areas where it alleges that a pharmaceutical company commits fraud. In addition, there is an emerging new area, adulterated products, where the DOJ is beginning to investigate and just may be the next huge compliance risk.
September 8, 2010
September 7, 2010
September 3, 2010
September 2, 2010
September 1, 2010
September 2, 2010
July 19, 2010
July 16, 2010
June 24, 2010
September 7, 2010
August 24, 2010
July 19, 2010
June 29, 2010
May 9, 2010
September 2, 2010
September 7, 2010
September 3, 2010
September 2, 2010
September 1, 2010
September 8, 2010
September 7, 2010
September 7, 2010
August 31, 2010
August 19, 2010
September 8, 2010
September 8, 2010
February 1, 2010
The "Massive News" theme by: Press75.com
|
Home |
About |
Contact |
Authors |
Write for CCI |
Article Guildelines |
Compliance News |
People on the Move |
Legal Notice |
Privacy Policy |
Corporate Compliance Insights is a professionally designed and managed forum dedicated to online discussion and analysis of corporate compliance and governance topics. Additionally, Corporate Compliance Insights is a focused knowledge-sharing forum designed to educate and encourage informed interaction within the corporate compliance community.
